Anti-cancer Drug Earthquake! Another New Anti-cancer Drug Has Obtained the Approval of the US FDA Clinical Trial!
Update time：2017-09-17 16:04:00 Views：
Recently, RiMO Therapeutics, Inc. (hereinafter referred to as “RiMO”), a company in which Kunming Pharmaceuticals holds a share, received a letter from US Food and Drug Administration (hereinafter referred to as “the US FDA”) for agreeing the new radiation therapy sensitizer RiMO-301 used for solid tumor treatment to conduct clinical trials, which indicates that the new drug has entered clinical trials in the United States.
It is understood that RiMO-301, which was approved by the US FDA for clinical trials, is a sensitizing drug developed primarily by RiMO based on a new radiation therapy technology platform for the treatment of head and neck cancer. Preclinical studies have shown that RiMO-301 degenerates/eliminates tumors in multiple cancer models when used in combination with low-dose X-ray radiation. RiMO-301 is expected to be widely used in many cancers, including head and neck cancer, cervical cancer, prostate cancer, and liver cancer. Currently, there are no similar drugs that have been listed.
Founded in August 2015, RiMO was established by Dr. Lin Wenbin, Professor James Franck, Distinguished Professor at the Department of Chemistry and Comprehensive Cancer Center of the University of Chicago. RiMO is a R&D company, mainly engaged in radiotherapy technology platforms and a series of new anti-cancer drugs based on this technology which is coming into clinical trials. In December 2016, Kunming Pharmaceuticals invested US$3 million in RiMO to acquire 9.91% of the company's shares, thus to enjoy the benefits derived from the rights to global market development of RiMO's R&D technological achievements on a pro-rata basis, a board seat and the priority negotiating rights for development of RiMO products in the Chinese market.
In US Central Time August 2017, RiMO filed a clinical trial application for RIMO-301 for solid tumor therapy to the US FDA and was recently approved. According to the relevant regulatory requirements for new drug development in the United States, the new drug still requires a series of clinical studies and is approved by the drug review department before it can be listed.
In recent years, Kunming Pharmaceuticals has made continuous efforts to enter the field of cancer treatment. In addition to investing in RiMO, Kunming Pharmaceuticals has established the North American Drug R&D Center in the United States, invested 2.5 million dollars, and participated in American CPI Corporation to researcha series of nanotechnology-based treatments for gastric cancer, colorectal cancer, and other anti-cancer drugs, unswervingly moving in the direction of international innovation and R&D. In the future, Kunming Pharmaceuticals will continue to develop innovative drugs and continue to seek suitable partners around the world for investment and mergers and acquisitions to enrich Kunming Pharmaceutical's product line and continuously improve its international competitiveness in the field of chronic disease treatment.